CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)
Sign informed consent;
Between the ages of 18 and 85;
Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).
Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
Patients with malignant tumor and other diseases and life expectancy of less than half a year;
Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension
Patients with pulmonary hypertension receiving targeted therapy
Cohort
Prospective
Not listed
Incidence of clinical worsening events 1 year after enrollment
All-cause death, Pulmonary hypertension progression associated with re-hospitalization, Progress of pulmonary hypertension disease
Incidence of all-cause death 1,3,5 year(s) after enrollment
Incidence of all-cause death 1,3,5 year(s) after enrollment
Click on the lead sponsor to view all of their trials.
